iC9-GD2 T cells

iC9-GD2 T cells are an investigational third-generation chimeric antigen receptor (CAR) T-cell therapy designed to treat relapsed or refractory neuroblastoma. These T cells are genetically engineered to express a CAR targeting the ganglioside GD2, an antigen highly expressed on neuroblastoma cells and other neuroectodermal tumors. The construct is unique for its inclusion of two costimulatory domains, CD28 and OX40 (TNFRSF4), which are intended to synergistically enhance the survival, expansion, and anti-tumor persistence of the cells. Furthermore, the therapy incorporates an inducible Caspase 9 (iC9) safety switch; this 'suicide switch' allows for the rapid elimination of the CAR-T cells via apoptosis upon the administration of a small-molecule chemical inducer of dimerization (CID), such as rimiducid, providing a mechanism to mitigate severe off-target toxicities or cytokine release syndrome.

Other names

iC9-GD2 CAR-T cellsiC-9-GD2 CAR-T cellsiC 9-GD2 CAR-T cellsGD2-specific iC9-CAR-T cellsGD-2-specific iC9-CAR-T cellsGD 2-specific iC9-CAR-T cellsiC9-GD2-CD28-OX40 CAR-T cellsiC-9-GD2-CD28-OX40 CAR-T cellsiC 9-GD2-CD28-OX40 CAR-T cellsGD2 CAR-T cellsGD-2 CAR-T cellsGD 2 CAR-T cells